Athersys MultiStem ARDS Trial Data Reported on WPVI 6 Action News Philadelphia . 1 year ago. 2017-01-05 Athersys stroke animation - MultiStem MoA . 3 years ago ...
May 05, 2020 · Since MultiStem is not virus- or pathogen-specific, it may have the potential to treat ARDS that develops from a variety of causes, including COVID-19, as well as other pathogen-induced or... The study is a randomized, double-blind, placebo-controlled, multi-center clinical trial evaluating the safety and efficacy of MultiStem therapy in subjects suffering moderate to moderate-severe ischemic strokes. Athersys expects initial results from the study to be disclosed around the end of the first quarter of 2015.
Acute respiratory distress syndrome (ARDS) can be brought on by COVID-19 and without any approved medication to treat it, patients can be put on a ventilator. Cleveland, Ohio-based Athersys has developed its MultiStem cell therapy and is studying it for COVID-19 related ARDS. Nov 23, 2015 · A study to examine the safety (and potential efficacy) of the adult stem cell investigational product, MultiStem, in adults who have Acute Respiratory Distress Syndrome (ARDS). The primary hypothesis is that MultiStem will be safe in ARDS patients. Steam Trading Cards related website featuring trading cards, badges, emoticons, backgrounds, artworks, pricelists, trading bot and other tools.